Pfizer-BioNTech COVID-19 vaccine

The Pfizer-BioNTech COVID-19 vaccine is a series of mRNA-based gene therapy products marketed as vaccines against COVID-19. The term is used to describe multiple versions of the product developed by Pfizer and BioNTech. Its official brand name is Comirnaty.

While initially referring primarily to BNT162b2 (the original formulation authorized for mass distribution) the names "Pfizer-BioNTech COVID-19 vaccine" and "Corminaty" are increasingly used to refer to subsequent reformulated versions, including those for the XBB.1.5 variant of SARS-CoV-2.

History

On December 6, 2024, U.S. District Judge Mark Pittman ordered the Food and Drug Administration (FDA) to disclose its Emergency Use Authorization (EUA) file for the Pfizer-BioNTech COVID-19 vaccine product to Public Health and Medical Professionals for Transparency (PHMPT).^[1]

National contracts

Albania

Between Pfizer, the Albanian Ministry of Health and Social Protection and the Institute of Public Health in Albania.

• January 6, 2021: Manufacturing and Supply Agreement

Brazil

Between Pfizer and the Ministry of Health of Brazil.

• March 18, 2021: Purchase Agreement

Canada

Between Pfizer and the Minister of Public Works and Government Services Canada on behalf of Public Services and Procurement Canada.

• October 26, 2020: Manufacturing and Supply Agreement

South Africa

Between Pfizer and the National Department of Health of South Africa.

• March 30, 2021: Manufacturing and Supply Agreement
• June 4, 2021: Amendment to Manufacturing and Supply Agreement
• Binding Term Sheet

Product monographs

Canada

• September 28, 2023: COMIRNATY® Omicron XBB.1.5

Studies

• February 1, 2021: “BNT162b vaccines protect rhesus macaques from SARS-CoV-2”
  • Published in Nature

External links

• Campfire Wiki
• Wikipedia
• Wikispooks